Convertible note offering removes restrictive secured debt and extends runway into 2028, supporting commercial launch. However, the massive debt load (~$701M) and potential dilution from conversion at ~$124.53/share cap upside. Monitor FDA PDUFA on July 17 — approval could de-risk the conversion premium. Preferred shares would benefit from the de-levering to unsecured debt.
Price Chart
Executive Summary
Celcuity is issuing $500M of 0.250% convertible senior notes due 2032 (plus $75M over-allotment). Net proceeds of ~$484.3M will fully repay the $137.9M secured term loan facility and fund working capital, commercial launch, and pipeline expansion through 2028. The de-levering to zero secured debt is a significant credit-positive event, but the large debt raise (~$201M prior converts + $500M new, totaling ~$701M) adds substantial leverage and potential dilution if converted.
Key Facts
- $500M aggregate principal of 0.250% convertible senior notes due 2032
- $75M over-allotment option, total $575M if fully exercised
- Initial conversion price ~$124.53/share, ~40% premium to $88.95 stock price on June 3
- Net proceeds ~$484.3M (or ~$557M with over-allotment)
- Proceeds to fully repay $137.9M secured term loan, eliminating all secured debt
- Post-offering, total long-term debt rises from $339.1M to $701.3M
- Maturity August 1, 2032; interest 0.250% paid semi-annually
- Not redeemable before August 6, 2029; convertible upon stock price conditions or certain corporate events
- Mandatory contingent conversion triggers if stock exceeds 130% of conversion price for 20 of 30 trading days
- FDA PDUFA date for gedatolisib NDA in PIK3CA WT breast cancer is July 17, 2026
- Positive Phase 3 VIKTORIA-1 MT data announced June 2, 2026 — sNDA planned Q3 2026
Financial Impact
De-levering: $137.9M secured debt eliminated; new debt: $500M-$575M. Net cash infusion ~$484M after expenses. Total debt rises from $339M to $701M. Prepayment fee of ~$2.6M incurred.
Risk Factors
- ~$701M total debt after offering significantly increases financial leverage
- Potential dilution from conversion: ~4M shares per $500M at $124.53, plus ~4M from existing 2031 converts at $51.30
- Unsecured notes rank equal with existing 2031 converts but effectively junior to any future secured debt
- No public trading market expected for the notes; illiquidity premium
- If stock does not appreciate above $124.53, convert notes remain out of the money — overhang without upside
- PIK element on prior term loan was expensive (~7.75%+2.85%); replacement with 0.25% coupon is cheaper but riskier (convertible)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-027395 |
| Exhibit: ex107.htm | 0001493152-26-027395 |
| Document: 0001493152-26-027395-index-headers.html | 0001493152-26-027395 |
| Document: 0001493152-26-027395-index.html | 0001493152-26-027395 |
| Document: 0001493152-26-027395.txt | 0001493152-26-027395 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 26, 2026 5w ago | 8-K | $95.08 $84.00 | ▼ −11.65% | ▼ −12.86% | $72.51 (−23.74%) |
Jul 15, 2026 11w ago | 144 | $91.51 $92.08 | ▼ −0.62% | ▲ +1.72% | $72.51 (+20.76%) |
Jul 14, 2026 11w ago | Press Release | $91.51 $92.08 | ▲ +0.62% | ▼ −1.72% | $72.51 (−20.76%) |
Jun 11, 2026 16w ago | Institutional Cluster | $89.49 $113.51 | ▲ +26.84% | ▲ +24.95% | $72.51 (−18.97%) |
Jun 8, 2026 16w ago | 8-K | $92.59 $115.72 | ▲ +24.98% | ▲ +23.53% | $72.51 (−21.69%) |
Jun 5, 2026 17w ago | 424B5 | $88.28 $108.58 | ▲ +23.00% | ▲ +21.13% | $72.51 (−17.86%) |
Jun 4, 2026 17w ago | Press Release | $92.47 $107.95 | ▲ +16.74% | ▲ +18.11% | $72.51 (−21.59%) |
Jun 3, 2026 17w ago | Press Release | $88.95 $107.95 | ▼ −21.36% | ▼ −22.36% | $72.51 (+18.48%) |
Jun 3, 2026 17w ago | 424B5 | $88.95 $107.95 | ▼ −21.36% | ▼ −22.36% | $72.51 (+18.48%) |
Jun 2, 2026 17w ago | 8-K | $91.42 $104.49 | ▲ +14.30% | ▲ +15.86% | $72.51 (−20.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access